There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTX – Research Report), Compugen (CGEN – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Lineage Cell Therapeutics (LCTX)
Robert W. Baird analyst Jack Allen initiated coverage with a Buy rating on Lineage Cell Therapeutics on November 14 and set a price target of $5.00. The company’s shares closed last Tuesday at $1.31.
According to TipRanks.com, Allen has 0 stars on 0-5 stars ranking scale with an average return of
Lineage Cell Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.40, representing a 285.7% upside. In a report issued on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Compugen (CGEN)
SVB Securities analyst Daina Graybosch maintained a Buy rating on Compugen on November 14 and set a price target of $8.00. The company’s shares closed last Tuesday at $0.87, close to its 52-week low of $0.51.
According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compugen with a $6.67 average price target, representing a 694.0% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.
Eli Lilly & Co (LLY)
SVB Securities analyst David Risinger maintained a Buy rating on Eli Lilly & Co on November 14. The company’s shares closed last Tuesday at $349.95, close to its 52-week high of $369.80.
According to TipRanks.com, Risinger is a 4-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $379.85, representing a 6.4% upside. In a report issued on November 14, Truist Financial also maintained a Buy rating on the stock with a $421.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LCTX:
- Mizuho Securities Reaffirms Their Buy Rating on Life Time Group Holdings (LTH)
- Mizuho Securities Reaffirms Their Buy Rating on Encompass Health (EHC)
- Activist Investor is Pushing Alphabet to Lay Off Employees and Curb Costs
- Transaction in Own Shares
- Berenberg Bank Keeps Their Buy Rating on Infineon Technologies AG (IFNNF)
